ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 18 filers reported holding ALPINE IMMUNE SCIENCES INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $956,000 | -40.7% | 248,992 | -38.8% | 0.03% | -53.0% |
| Q3 2019 | $1,611,000 | -8.0% | 406,926 | -2.2% | 0.07% | +4.8% |
| Q2 2019 | $1,751,000 | -46.3% | 415,908 | -12.5% | 0.06% | -49.6% |
| Q1 2019 | $3,262,000 | +86.4% | 475,450 | 0.0% | 0.12% | +78.6% |
| Q4 2018 | $1,750,000 | -54.9% | 475,450 | -22.4% | 0.07% | -49.6% |
| Q3 2018 | $3,879,000 | -43.9% | 612,867 | -32.9% | 0.14% | -42.8% |
| Q2 2018 | $6,912,000 | -5.4% | 913,100 | 0.0% | 0.24% | -4.0% |
| Q1 2018 | $7,305,000 | -28.6% | 913,100 | 0.0% | 0.25% | -37.1% |
| Q4 2017 | $10,227,000 | -5.5% | 913,100 | -2.1% | 0.40% | -17.6% |
| Q3 2017 | $10,824,000 | – | 933,100 | – | 0.49% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 3,056,420 | $22,006,000 | 19.85% |
| Decheng Capital Management III (Cayman), LLC | 6,708,288 | $48,300,000 | 17.51% |
| GREAT POINT PARTNERS LLC | 3,448,521 | $24,829,000 | 5.98% |
| Omega Fund Management, LLC | 2,029,580 | $14,613,000 | 5.35% |
| Paradigm Biocapital Advisors LP | 2,214,722 | $15,946,000 | 2.13% |
| Frazier Life Sciences Management, L.P. | 2,985,757 | $21,497,000 | 1.66% |
| COMMODORE CAPITAL LP | 1,325,000 | $9,540,000 | 1.53% |
| Octagon Capital Advisors LP | 1,225,000 | $8,820,000 | 1.52% |
| RA Capital Management | 4,356,632 | $31,368,000 | 0.67% |
| TCG Crossover Management, LLC | 254,569 | $1,833,000 | 0.55% |